Artificial intelligence in bioinformatics pays off today where the job is pattern recognition on large, well-characterised data: classifying, clustering and annotating sequences and readouts, increasingly on top of pretrained protein or DNA embeddings. Generative design and general-purpose language models acting as end-to-end analysts are still exploratory. A second line matters as much as the first: output that feeds a GxP decision has to come from a workflow validated end to end, with software and database versions documented.
The wider picture of where pattern recognition earns its keep across AI in life sciences is covered separately. This page stays with bioinformatics and lab workflows, and with the evidence those workflows have to produce.
Which bioinformatics workflows pay back now, and which are still experiments?
The mature work is unglamorous. Classification, prediction and feature selection are standard machine-learning tasks in bioinformatics, and clustering in particular is central to analysing high-dimensional sequence, expression and image data. What has changed is the quality of the pretrained representations those methods start from. A 2025 systematic review of 68 studies on generative AI in bioinformatics (published 2021 to 2025, posted on arXiv) reports that embedding-based protein models such as ESM-2 and ProtT5 consistently surpass classical alignment tools including BLAST, Foldseek and DALI on functional annotation. The same review reports that pretrained embeddings let shallow, cheap models match or beat deeper architectures, so embedding quality often matters more than model complexity.
Genomic language models such as DNABERT outperformed CNN and RNN baselines on defined prediction tasks (promoters, transcription factor binding sites, splice sites). How generative language models reading DNA do this is a topic of its own.
The experimental side is equally clear in the evidence. On the BixBench benchmark, the review reports that GPT-4o reached about 9% accuracy on open-ended multi-step bioinformatics analysis and Claude 3.5 Sonnet about 17%, with both at random levels in multiple-choice settings. Domain-specific models consistently outperform general-purpose LLMs on bioinformatics tasks, and the review’s reading is that raw compute cannot replace the knowledge held in well-curated biological datasets. Generative protein and molecule design for AI drug discovery is promising, but functional validity and safety still need systematic experimental validation.
Where each workflow stands
| Workflow | Status | What the evidence shows |
|---|---|---|
| Protein function annotation from pretrained embeddings | Mature | ESM-2 and ProtT5 embeddings surpass BLAST, Foldseek and DALI; ESM-2 (650M) reached CAFA3 Fmax of 0.542, 0.619 and 0.693 across the three Gene Ontology categories (2025 systematic review) |
| Genomic sequence prediction (promoters, binding sites, splice sites) | Mature for defined tasks | DNABERT outperformed CNN and RNN baselines without large labelled datasets |
| Alignment-free structure prediction | Fast enough for metagenomic scale | ESMFold predicts about 60 times faster than AlphaFold2, making structural interpretation of 617M metagenomic proteins feasible |
| Batch correction for image-based screening | Effective in some scenarios | Harmony and Seurat gave the best balance of batch removal and biological signal, but no method coped with more than a few hundred compounds across more than one microscope type (Nature Communications, 2024) |
| General LLM as a multi-step analyst | Experimental | About 9% (GPT-4o) and 17% (Claude 3.5 Sonnet) on open-ended BixBench tasks |
| LLM orchestrating established tools | Early, promising | Grounding outputs in tools such as BLAST improves factual reliability and limits hallucination |
| Generative protein and molecule design | Exploratory | Requires systematic experimental validation and better interpretability |
The figures above are accuracy and speed results, not measures of financial return. Our reading is that payback follows from those numbers only where the improved step was the one holding the workflow up, which is why the next question matters more than any league table.
Two limits cut across the whole table. Training databases skew towards well-studied organisms and medically important human genes, so models perform worse on understudied biology. And hallucination is a real risk in scientific use, from generating incorrect workflow code to fabricating enzyme-substrate interactions.
Which lab tasks should AI take on, and which belong with lab staff?
The useful question is where the bottleneck sits, not how many people a model could replace. Pattern recognition earns its place on high-volume readouts where a reviewer currently spends time triaging data that is mostly unremarkable: annotation candidates, image-based profiles, quality flags on sequencing runs. Language models are genuinely useful for work that is itself expressed in language, such as reading literature, extracting information from documents, comparing records, drafting text and writing code. The 2025 review likewise notes that language models have become valuable help with the complex scripting that bioinformatics workflows depend on.
Some tasks stay with people by design. FDA’s NGS guidance treats interpretation of a variant’s clinical significance for an individual patient, done by healthcare and laboratory professionals, as outside the test itself. Signatures stay human too. PharmTech reported in 2026 that FDA gave inappropriate AI use its own subsection in an April 2026 warning letter, after AI-generated specifications and master production records went into use without adequate quality-unit review. The work can be split between a person and a model; the accountability cannot.
EU draft Annex 22 makes the trade explicit. Depending on process criticality and how thoroughly the model was tested, human review may need to cover every output, so the less assurance the model carries, the more the human control layer has to carry. A model that saves reviewer time on paper but forces review of every output has moved the bottleneck, not removed it.
Where does predictive analytics actually earn its keep in pharma analytical operations?
Predictive analytics earns its keep in analytical operations when the model has a defined use, frozen parameters and acceptance criteria agreed before testing, and it stays a slide-deck claim when none of those exist. The Annex 22 draft sets out that machinery: intended use including rare inputs, pre-approved test metrics, test data walled off from training, confidence thresholds that force an “undecided” flag instead of an unreliable answer, and drift monitoring on the input space. FDA’s January 2025 draft gives a worked example of the same logic: an AI model estimating fill volume carries low influence when release testing still measures a representative sample of each batch, which brings the overall model risk down to medium.
The full treatment of forecasting and process-drift detection in predictive analytics in pharma lives on its own page. The point for a bioinformatics lab is narrower: a prediction that nobody has scoped, tested on independent data or monitored is not yet an analytical capability.
How should a lab decide which bioinformatics outputs feed regulated (GxP) decisions versus exploratory research, given that the validation burden diverges sharply between the two?
Decide by what the output will be used for, not by which model produced it. FDA’s January 2025 draft guidance on AI for regulatory decision-making covers AI that produces information supporting decisions on drug safety, effectiveness or quality, and explicitly excludes drug discovery and operational-efficiency uses that do not affect patient safety, drug quality or study reliability. Within scope, the draft makes credibility activities commensurate with model risk, which it defines as model influence (how much the decision rests on the AI output relative to other evidence) combined with decision consequence.
The European view is broader in one respect. EMA’s reflection paper, adopted in September 2024, sets out principles for AI and machine learning at any step of a medicine’s lifecycle, from drug discovery to post-authorisation. Discovery output therefore falls outside FDA’s draft but not outside EMA’s principles.
Once NGS output feeds a GxP decision, validation extends to the whole process. In GxP NGS work, sequencing instruments, bioinformatics software and data handling are validated as one end-to-end process rather than component by component. FDA’s NGS guidance (written for germline diagnostic tests) asks for the finalised pipeline to be part of end-to-end validation, modifications including software updates to be documented, and end-to-end revalidation where a risk assessment calls for it.
| Question to settle | Exploratory output | Output feeding a GxP decision |
|---|---|---|
| Regulatory frame | Discovery uses fall outside FDA’s January 2025 AI credibility draft | In scope when the output supports a safety, effectiveness or quality decision |
| Validation unit | Fitness for the research question, judged by the scientist | Instruments, software and data handling validated as a single process |
| Change handling | Record what changed so results can be re-run | Document modifications, keep a revalidation SOP, revalidate end to end where risk requires |
| Reference data | Pin versions as good practice | Record database versions and have a procedure for incorporating updates |
| Test data | Held-out split | Independent of development data and never shown to the model in training |
| Model type (EU manufacturing) | Any, including generative | Annex 22 draft covers static, deterministic models; generative AI and LLMs kept out of critical GMP use |
FDA credibility versus EU Annex 22
The two regulators do not frame the problem in the same way. FDA’s January 2025 draft proposes a risk-based credibility assessment for a defined context of use rather than validation of the model as a system. The EU’s July 2025 draft Annex 22 covers machine learning models whose parameters are frozen and whose outputs are deterministic, and states that generative AI and large language models should not be used in critical GMP applications. The same draft allows generative models in non-critical applications where qualified staff confirm the output suits its intended use. PharmTech’s 2026 analysis argues that the exclusion may soften, but that any route into critical use will still need the system, user, version and use case qualified together.
Where bioinformatics output moves into manufacturing and quality-by-design work, AI and data analytics in pharma manufacturing covers that terrain, including explainability in process models.
What makes an AI-assisted bioinformatics analysis reproducible enough to submit?
One demonstrated route is to submit the analysis as a reproducible, reviewable object rather than describe it in prose. A 2020 proof-of-concept study on BioCompute Objects (the IEEE 2791-2020 standard) submitted an NGS analysis to FDA as a verification kit made up of the initial data and a template BioCompute Object, and FDA reanalysed the data with its own pipeline. Of 118 simulated patient samples, 117 (99.15%) agreed, and only 2 of 242 variant calls (0.8%) disagreed under the stated thresholds. The FDA reviewer concluded that the submission gave enough information to carry out a regulatory review.
A BioCompute Object records provenance, metadata, execution environment, parameters, inputs and outputs, and abstracts the analysis so it does not depend on a particular platform or tool. That is the documentation half. FDA’s NGS guidance supplies the version half: software names and versions, modifications to open-source tools, whether the pipeline runs locally or in the cloud, reference assembly accession and version, and database versions.
An AI step adds obligations on top of that. FDA’s January 2025 draft asks for development data that is relevant and reliable (accurate, complete and traceable), software version changes that are tracked, and performance metrics reported with confidence intervals. The results go into a credibility assessment report, either submitted or held for inspection, and life cycle plans covering monitoring frequency and retesting triggers belong in the pharmaceutical quality system. For hosted models the hard part is change control: a provider can update or retire a model on its own schedule, so pinned versions on infrastructure you control, with a record of which version produced each output, make the process workable.
Checklist for a submission-ready AI-augmented analysis
- A written context of use stating the question, the model’s role and what other evidence sits alongside it.
- Raw data and the template workflow description packaged as a verification kit for review.
- Software, model, database and reference assembly versions recorded for every output.
- Independent test data and performance metrics with confidence intervals.
- A revalidation procedure triggered by pipeline, model or database changes.
- A monitoring plan with stated retesting triggers.
TechnoLynx treats this kind of approval-grade evidence as an engineering output in its own right: evaluations, version records and lineage that an auditor or quality owner can read and sign against, produced as engineering rather than as policy advice, and never as regulatory sign-off. The version pinning, lineage capture and performance monitoring behind such a pack are core MLOps engineering disciplines.
How do we run pattern recognition across high-throughput screening without building reproducibility debt?
Reproducibility debt in screening builds up from two well-documented sources: computational practice and the lab bench. The 2017 Nature Biotechnology paper introducing Nextflow identified poor software and database practice as the main source of computational irreproducibility in large analyses, with small numerical differences across computing platforms adding instability on HPC systems. Its answer was a workflow manager that runs each step in Docker containers. The 2020 nf-core paper adds that pipelines remain hard to reproduce across systems and institutions because of differing hardware, operating systems and software versions, and that implementations are usually built case by case even where guidelines such as GATK best practices exist.
The second source is the lab bench. Batch effects are variations that come from reagent lots, processing times, equipment calibration or platforms rather than biology. A benchmark on JUMP Cell Painting data, gathered across 13 sites and covering 116,753 compound perturbations, found that performance dropped most across microscope types. In the hardest scenarios, with more than a few hundred compounds and more than one microscope type, none of the methods removed batch effects adequately. Biological signal survived substantial batch effects only so long as batch was not confounded with the experimental factors.
Several practical constraints follow from that benchmark. FastMNN, MNN, Scanorama and Harmony must recompute the correction across the whole dataset whenever new profiles arrive, while methods that avoid recomputation give no guarantee on data from an unseen source. A screening pipeline that keeps adding plates therefore has to budget for recomputation and for re-checking earlier results, or accept the weaker guarantee. Upstream, keep batch from lining up with the perturbation, and run a shared positive-control plate with every batch, as JUMP did with its 302-compound control plate.
Where is the boundary between data engineering and AI work in a biotech lab?
The boundary sits at the analysis step. A standard description of machine learning on biological data has four stages: recording (capture, storage and merging of sources), preprocessing (cleaning, correction, imputation and variable selection), analysis with supervised or unsupervised models, and visualisation and interpretation. Recording and preprocessing are data engineering; analysis is where the model lives. Data-quality problems such as duplicates, experimental errors, typing mistakes and non-standardised methods are settled, or not, before any model sees the data.
Software and database practice, not modelling, is the main cause of computational irreproducibility in the Nextflow paper’s analysis, and the documentation items FDA’s NGS guidance lists (software versions, reference assemblies, databases, filtering thresholds) describe pipeline and data handling rather than a learned model.
Which handovers should each stage of a lab’s data pipeline produce?
What follows is the minimum set of handovers the regulatory and reproducibility literature asks of each stage, not a reference architecture for any particular facility.
- Instrument output. Sequencers and imagers write raw files (FASTQ for sequencing) that are retained, because FDA reviewers of antiviral NGS submissions ask for the raw fastq files.
- Workflow execution. A workflow manager such as Nextflow runs containerised steps, reducing the platform differences that break reproducibility across clusters and sites.
- Versioned reference data. Reference assemblies, annotation databases and control plates are pinned and recorded per run.
- Model step. Pattern recognition runs as one step of the pipeline, with its own pinned version and logged inputs and outputs.
- Review and release. Model outputs feeding regulated decisions get human review scaled to process criticality and model testing, up to every output.
- Lineage record. Each result carries provenance, parameters and execution environment, in a form such as a BioCompute Object.
- Monitoring. Model performance and input drift are tracked against stated retesting triggers.
How this plays out alongside lab automation and instruments is the subject of modern biotech labs, automation, AI and data.
The model step is the only one that is specifically “AI”. The other steps decide whether its output can be trusted, re-run and defended. The open question for most regulated labs is not which model to pick but how far into the pipeline they extend the validated state, and that answer changes as the final text of Annex 22 and FDA’s credibility guidance settle.
FAQ
Is AI going to replace bioinformatics?
Not on current evidence. General-purpose LLMs scored about 9% to 17% on open-ended multi-step bioinformatics tasks in the BixBench benchmark, and the field is moving towards systems where a language model coordinates established bioinformatics tools rather than replacing them.
What is the best AI tool for bioinformatics?
No single tool is best across tasks. Smaller domain-specific models generally outperform large general-purpose models on specialised bioinformatics problems, so the right choice depends on the data type and task.
How can AI be used in bioinformatics?
Machine learning in bioinformatics is used for prediction, classification, and feature detection and selection, across tasks such as gene finding, protein function annotation and microbiome analysis.
